PNOC023
Clinical trial of ONC206 for the treatment of diffuse midline gliomas (DMG) and other progressive or recurrent tumours of the brain and spinal cord
The novel agent ONC206 may be able to inhibit the growth of tumor cells. This international phase 1 study is investigating the effects and the optimal dose of ONC206 alone or in combination with radiotherapy. The study includes patients with a diffuse midline glioma that is newly diagnosed or has grown again or come back (progression/relapse). It also includes patients with other malignant tumors of the central nervous system (brain and spinal cord) that have grown again or come back. In patients scheduled for a tumor biopsy, treatment with ONC206 can be started shortly before the biopsy (target validation). Most of the treatment is given at home. After a screening stay of several days in hospital, study visits take place once a week for about 4 weeks and once a month after that. Depending on the clinical situation, the treatment is given during radiotherapy or only afterwards.
Is this study suitable for my child’s condition?
Leukaemia, lymphoma and bone marrow disease
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Severe aplastic anemia (SAA)
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Other leukaemia, lymphoma and bone marrow disease
Brain and spinal cord tumors
- Low-grade glioma
- High-grade glioma
- Diffuse-intrinsic pontine glioma (DIPG) / Diffuse midline glioma (DMG)
- Medulloblastoma
- Atypical teratoid rhabdoid tumours (ATRT)
- Ependymoma
- Germ cell tumours / germinoma / nongerminomatous germ cell tumours / teratoma (brain / spinal cord)
- Craniopharyngioma
- Other brain tumours or spinal cord tumours
Solid tumors
- Wilms tumours / nephroblastoma
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing sarcoma
- Osteosarcoma
- Rhabdoid tumours (other than brain or spinal cord)
- Other sarcoma
- Germ cell tumours (other than brain or spinal cord)
- Retinoblastoma
- Hepatoblastoma
- Other solid tumours
Study Information
What age range of children can participate?
2 - 21 years
Official Study Information
Study at www.humanforschung-schweiz.ch
Study at www.clinicaltrials.gov
Questions? Please contact your medical team.
If you would like more information about a study, please speak to your child’s treating physician. They are your primary point of contact and can provide personalized advice and support. If no treatment team is currently in place, you can find general contact information for the study sites on the map below.
Treatment Centers with Open Study – Map & Overview
The map shows all treatment sites in Switzerland. Locations where the study is currently open are marked in blue. You can find contact details by clicking on the towns. The information on study sites is updated regularly. However, a study may occasionally open at a new site before this is reflected on the platform. If in doubt, please contact your treatment team or one of the listed clinics directly.
Zürich
Universitäts-Kinderspital Zürich –
Eleonorenstiftung
Lenggstrasse 30
8008 Zürich
https://www.kispi.uzh.ch
Sekretariat Onkologie
Telefon: +41 44 249 63 50
E-Mail: onkologie.sekretariat@kispi.uzh.ch